Development Agreements in the Pharmaceuticals Industry

317 Contracts & Agreements

Browse by Company

ACURA PHARMACEUTICALS, INC (1 contract)
Adamis Pharmaceuticals Corp (1)
Akorn (2)
ALDER BIOPHARMACEUTICALS INC (4)
Alexza Pharmaceuticals Inc. (3)
Altus Pharmaceuticals Inc. (5)
AMYLIN PHARMACEUTICALS INC (1)
Amylyx Pharmaceuticals, Inc. (1)
ANADYS PHARMACEUTICALS INC (8)
ANI Pharma Inc (3)
Anthera Pharmaceuticals Inc (2)
Aquestive Therapeutics, Inc. (2)
ARADIGM CORP (3)
AUXILIUM PHARMACEUTICALS INC (5)
AVALON PHARMACEUTICALS INC (1)
Bausch Health Companies Inc. (1)
BIODELIVERY SCIENCES INTERNATIONAL INC (1)
Biostar Pharmaceuticals, Inc. (1)
Bristol-Myers Squibb (2)
CADENCE PHARMACEUTICALS INC (2)
Canbiola, Inc. (1)
CANNAPOWDER, INC. (1)
CARDAX, INC. (1)
CELGENE CORP (4)
CHINA PEDIATRIC PHARMACEUTICALS, INC. (3)
CHINA PHARMA HOLDINGS, INC. (1)
China QinBa Pharmaceuticals, Inc. (2)
Citius Pharmaceuticals, Inc. (2)
CNS Pharmaceuticals, Inc. (1)
Context Therapeutics Inc. (5)
Corcept Therapeutics Incorporated (1)
CorMedix Inc. (2)
CUBIST PHARMACEUTICALS INC (2)
CymaBay Therapeutics, Inc. (2)
DURECT CORP (3)
ELITE PHARMACEUTICALS INC (3)
EPIX Pharmaceuticals, Inc. (3)
Eton Pharmaceuticals, Inc. (4)
Exactus, Inc. (1)
Furiex Pharmaceuticals, Inc. (2)
GFR PHARMACEUTICALS INC (2)
Horizon Pharma plc (4)
Hoth Therapeutics, Inc. (1)
IntelGenx Technologies Corp. (2)
JAVELIN PHARMACEUTICALS, INC (2)
Jazz Pharmaceuticals plc (5)
Kaleido Biosciences, Inc. (1)
Kannalife Inc (34)
KID CASTLE EDUCATIONAL CORP (3)
KING PHARMACEUTICALS INC (6)
Lexaria Bioscience Corp. (1)
Liquidia Corp (1)
Lumena Pharmaceuticals, Inc. (1)
MARINUS PHARMACEUTICALS INC (2)
MEMORY PHARMACEUTICALS CORP (1)
Merck (2)
MiddleBrook Pharmaceuticals, Inc. (3)
MJ Holdings, Inc. (1)
Molecular Insight Pharmaceuticals, Inc. (2)
Nabriva Therapeutics plc (1)
NEKTAR THERAPEUTICS (2)
NewBridge Global Ventures, Inc. (1)
Novan, Inc. (2)
NPS PHARMACEUTICALS INC (1)
OMEROS CORP (4)
ONYX PHARMACEUTICALS INC (1)
OPIANT PHARMACEUTICALS, INC. (4)
OPTIMER PHARMACEUTICALS INC (1)
OSI PHARMACEUTICALS INC (12)
Paratek Pharmaceuticals, Inc. (2)
Pivot Pharmaceuticals Inc. (1)
PLx Pharma Inc. (2)
PREDIX PHARMACEUTICALS HOLDINGS INC (1)
Provention Bio, Inc. (2)
Pulmatrix, Inc. (4)
REATA PHARMACEUTICALS INC (1)
Recro Pharma, Inc. (4)
RespireRx Pharmaceuticals Inc. (2)
Revance Therapeutics, Inc. (3)
ROCK CREEK PHARMACEUTICALS, INC. (14)
Royalty Pharma plc (10)
Sagent Pharmaceuticals, Inc. (2)
SALIX PHARMACEUTICALS LTD (2)
Scopus BioPharma Inc. (8)
scPharmaceuticals Inc. (1)
Shuttle Pharmaceuticals, Inc. (1)
SIGA TECHNOLOGIES INC (31)
The Medicines Company (2)
Theravance Biopharma, Inc. (3)
TIBET PHARMACEUTICALS, INC. (1)
United Cannabis Corp (3)
Valera Pharmaceuticals Inc (1)
Verona Pharma plc (1)
Verrica Pharmaceuticals Inc. (1)
VIA Pharmaceuticals, Inc. (6)
VICURON PHARMACEUTICALS INC (1)
Virpax Pharmaceuticals, Inc. (4)
XERIS PHARMACEUTICALS INC (1)
Zomedica Pharmaceuticals Corp. (3)
Zynerba Pharmaceuticals, Inc. (3)

Recent Contracts

Amendment of Solicitation/Modification of Contract 00016, dated July 18, 2024, to Agreement, dated September 10, 2018, by and between SIGA and the Biomedical Advanced Research and... (SIGA TECHNOLOGIES INC, Filed With SEC on August 1, 2024)
Amendment of Solicitation/Modification of Contract 00015, dated February 9, 2024, to Agreement, dated September 10, 2018, by and between SIGA and the Biomedical Advanced Research... (SIGA TECHNOLOGIES INC, Filed With SEC on March 12, 2024)
Amendment of Solicitation/Modification of Contract 00014, dated October 18, 2023, to Agreement, dated September 10, 2018, by and between SIGA and the Biomedical Advanced Research... (SIGA TECHNOLOGIES INC, Filed With SEC on March 12, 2024)
Third Amendment to Development and Commercialization Agreement, dated January 6, 2024, by and between the Company, Pulmatrix Operating Company, Inc., and Cipla Technologies LLC (Pulmatrix, Inc., Filed With SEC on January 8, 2024)
Amendment of Solicitation/Modification of Contract 000024, dated September 21, 2023, to Agreement, dated June 1, 2011, by and between SIGA and the Biomedical Advanced Research and... (SIGA TECHNOLOGIES INC, Filed With SEC on November 7, 2023)
Amendment of Solicitation/Modification of Contract 00013, dated July 27, 2023, to Agreement, dated September 10, 2018, by and between SIGA and the Biomedical Advanced Research and... (SIGA TECHNOLOGIES INC, Filed With SEC on August 8, 2023)
Technology Transfer Contract, dated November 28, 2022, between Hainan Helpson Medical & Biotechnology Co., Ltd and Chengdu Bonier Medical Technology Development Co., Ltd (CHINA PHARMA HOLDINGS, INC., Filed With SEC on December 2, 2022)
Development and Manufacturing Services Agreement, dated November (Context Therapeutics Inc., Filed With SEC on November 9, 2022)
Amendment No. 3 to Process Development Agreement (Context Therapeutics Inc., Filed With SEC on November 9, 2022)
Amendment of Solicitation/Modification of Contract 000022, dated September 29, 2022, to Agreement, dated May 13, 2011, by and between SIGA and the Biomedical Advanced Research and... (SIGA TECHNOLOGIES INC, Filed With SEC on November 3, 2022)
Amendment of Solicitation/Modification of Contract 000021, dated September 28, 2022, to Agreement, dated May 13, 2011, by and between SIGA and the Biomedical Advanced Research and... (SIGA TECHNOLOGIES INC, Filed With SEC on November 3, 2022)
Amendment of Solicitation/Modification of Contract 000012, dated August 5, 2022, to Agreement, dated September 10, 2018, by and between SIGA and the Biomedical Advanced Research... (SIGA TECHNOLOGIES INC, Filed With SEC on November 3, 2022)
Amendment of Solicitation/Modification of Contract 000011, dated July 26, 2022, to Agreement, dated September 10, 2018, by and between SIGA and the Biomedical Advanced Research... (SIGA TECHNOLOGIES INC, Filed With SEC on November 3, 2022)
Amendment of Solicitation/Modification of Contract 00010, dated March 29, 2022, to Agreement, dated September 10, 2018, by and between SIGA and the Biomedical Advanced Research... (SIGA TECHNOLOGIES INC, Filed With SEC on November 3, 2022)
Amendment of Solicitation/Modification of Contract 00009, dated January 27, 2022, to Agreement, dated September 10, 2018, by and between SIGA and the Biomedical Advanced Research... (SIGA TECHNOLOGIES INC, Filed With SEC on November 3, 2022)
Amendment No. 2, dated September 21, 2022, by and between Marinus Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority, a division of the U.S.... (MARINUS PHARMACEUTICALS INC, Filed With SEC on September 23, 2022)
Amendment of Solicitation/Modification of Contract 000023, dated February 15, 2022, to Agreement, dated June 1, 2011, by and between SIGA and the Biomedical Advanced Research and... (SIGA TECHNOLOGIES INC, Filed With SEC on May 5, 2022)
American Development Partners development agreement (Canbiola, Inc., Filed With SEC on April 15, 2022)
Amendment, dated March 29, 2022, by and between Marinus Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority, a division of the U.S. Department of... (MARINUS PHARMACEUTICALS INC, Filed With SEC on March 31, 2022)
Amendment Agreement by and between Verona Pharma plc and Ligand UK Development Limited dated March 24, 2022 (Verona Pharma plc, Filed With SEC on March 30, 2022)
Amendment of Solicitation/Modification of Contract 00022, dated November 8, 2021, to Agreement, dated June 1, 2011, by and between SIGA and the Biomedical Advanced Research and... (SIGA TECHNOLOGIES INC, Filed With SEC on March 3, 2022)
Amendment of Solicitation/Modification of Contract 00020, dated November 8, 2021, to Agreement, dated May 13, 2011, by and between SIGA and the Biomedical Advanced Research and... (SIGA TECHNOLOGIES INC, Filed With SEC on March 3, 2022)
Amendment of Solicitation/Modification of Contract 00008, dated December 9, 2021, to Agreement, dated September 10, 2018, by and between SIGA and the Biomedical Advanced Research... (SIGA TECHNOLOGIES INC, Filed With SEC on March 3, 2022)
Amendment of Solicitation/Modification of Contract 00006, dated April 29, 2021, to Agreement, dated September 10, 2018, by and between SIGA and the Biomedical Advanced Research... (SIGA TECHNOLOGIES INC, Filed With SEC on March 3, 2022)
Development Funding and Royalties Agreement, dated May 4, 2019, by and between Novan, Inc. and Ligand Pharmaceuticals Incorporated (Novan, Inc., Filed With SEC on February 18, 2022)
Research, Development and Supply Agreement, dated as of December 9, 2019, and Deed of Amendment, dated as of July 26, 2021, by and between the Registrant and ICE S.p.A. (formerly... (Amylyx Pharmaceuticals, Inc., Filed With SEC on December 16, 2021)
Development Financing Agreement, dated July 30, 2021, by and between CymaBay Therapeutics, Inc. and ABW Cyclops SPV LP (CymaBay Therapeutics, Inc., Filed With SEC on November 10, 2021)
Second Amendment to Development and Commercialization Agreement (Pulmatrix, Inc., Filed With SEC on November 9, 2021)
Modification of Contract No. 3, dated September 23, 2021, between Paratek Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority of the United States... (Paratek Pharmaceuticals, Inc., Filed With SEC on November 8, 2021)
Modification of Contract No. 2, dated July 29, 2021, between Paratek Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority of the United States... (Paratek Pharmaceuticals, Inc., Filed With SEC on November 8, 2021)
Amendment of Solicitation/Modification of Contract 0007, dated September 8, 2021, to Agreement, dated September 10, 2018, by and between SIGA and the Biomedical Advanced Research... (SIGA TECHNOLOGIES INC, Filed With SEC on November 4, 2021)
Agreement for Rendering of Research Services between Virpax Pharmaceuticals, Inc. and Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd., dated June... (Virpax Pharmaceuticals, Inc., Filed With SEC on September 9, 2021)
Amendment No. 2 to Process Development Agreement, dated June 3, 2021, between Context Therapeutics LLC and Tyligand Bioscience (Shanghai) Limited (Context Therapeutics Inc., Filed With SEC on June 16, 2021)
Amendment No. 1 to Process Development Agreement, dated April 21, 2021, between Context Therapeutics LLC and Tyligand Bioscience (Shanghai) Limited (Context Therapeutics Inc., Filed With SEC on May 27, 2021)
Process Development Agreement, dated March 6, 2020, between Context Therapeutics LLC and Tyligand Bioscience (Shanghai) Limited (Context Therapeutics Inc., Filed With SEC on May 27, 2021)
Corporate Advisory Agreement (Research & Development) between the Company and GYB, LLC dated May 18, 2021 (MJ Holdings, Inc., Filed With SEC on May 21, 2021)
Strategic Development Agreement dated March 14, 2021 (IntelGenx Technologies Corp., Filed With SEC on March 25, 2021)
Development and Commercialization Agreement by and between Theravance Biopharma R&D, Inc. and Mylan Ireland Limited, dated January 30, 2015 (Theravance Biopharma, Inc., Filed With SEC on February 26, 2021)
Agreement for the Rendering of Research Services by and between Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. and Virpax Pharmaceuticals, Inc.,... (Virpax Pharmaceuticals, Inc., Filed With SEC on November 20, 2020)
Agreement for the Rendering of Research Services by and between Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. and Virpax Pharmaceuticals, Inc.,... (Virpax Pharmaceuticals, Inc., Filed With SEC on November 20, 2020)